Renaissance of cancer therapeutic antibodies

Drug Discovery Today

Volumn 8, Issue 11, 2003, Pages 503-510

  Glennie, Martin J ^a   Van De Winkel, Jan G J ^b,c  

^a UNIVERSITY OF SOUTHAMPTON   (United Kingdom)

^b GENMAB   (Netherlands)

^c University Medical Center   (Netherlands)

Author keywords

Antibodies; Apoptosis; Biochemistry; Cancer biology; Cancer therapy; Cell biology; Drug Discovery; Molecular Medicine; Pharmaceutical Science; Specificity

Indexed keywords

ABCIXIMAB; ADALIMUMAB; ALEMTUZUMAB; BASILIXIMAB; BEVACIZUMAB; CALICHEAMICIN; CETUXIMAB; DACLIZUMAB; GEMTUZUMAB OZOGAMICIN; IBRITUMOMAB TIUXETAN; IMMUNOGLOBULIN G; INFLIXIMAB; MONOCLONAL ANTIBODY; OKT 3; PALIVIZUMAB; RITUXIMAB; TOSITUMOMAB I 131; TRASTUZUMAB;

APOPTOSIS; BIOTRANSFORMATION; CANCER THERAPY; CHIMERA; CYTOTOXICITY; GENETIC ENGINEERING; HUMAN; NONHUMAN; REVIEW; SIGNAL TRANSDUCTION;

ANIMALS; ANTIBODIES, MONOCLONAL; APOPTOSIS; HUMANS; NEOPLASMS; RATS;

EID: 0038347495     PISSN: 13596446     EISSN: None     Source Type: Journal    
DOI: 10.1016/S1359-6446(03)02714-4     Document Type: Review

References (39)

1. Gura T. Therapeutic antibodies: magic bullets hit the target. Nature. 417:2002;584-586.
2. Kohler G., Milstein C. Continuous cultures of fused cells secreting antibody of predefined specificity. Nature. 256:1975;495-497.
3. Winter G., Milstein C. Man-made antibodies. Nature. 349:1991;293-299.
4. Cragg M.S., et al. Signaling antibodies in cancer therapy. Curr. Opin. Immunol. 11:1999;541-547.
5. Deo Y.M., et al. Clinical significance of IgG Fc receptors and Fc gamma-directed immunotherapies. Immunol. Today. 18:1997;127-135.
6. Kretzschmar T., von Ruden T. Antibody discovery: phage display. Curr. Opin. Biotechnol. 13:2002;598-602.
7. Kellermann S.A., Green L.L. Antibody discovery: the use of transgenic mice to generate human monoclonal antibodies for therapeutics. Curr. Opin. Biotechnol. 13:2002;593-597.
8. Lonberg N., et al. Antigen-specific human antibodies from mice comprising four distinct genetic modifications. Nature. 368:1994;856-859.
9. Van Dijk M.A., Van de Winkel J.G.J. Human antibodies as next generation therapeutics. Curr. Opin. Chem. Biol. 5:2001;368-374.
10. Van Den Brande J.M., et al. Treating Crohn's disease by inducing T lymphocyte apoptosis. Ann. N. Y. Acad. Sci. 973:2002;166-180.
11. Morgan B.P., et al. Role of complement in inflammation and injury in the nervous system. Exp. Clin. Immunogenet. 14:1997;19-23.
12. Kirschfink M. Targeting complement in therapy. Immunol. Rev. 180:2001;177-189.
13. Hale G., et al. Alemtuzumab (Campath-1H) for treatment of lymphoid malignancies in the age of non-myeloablative conditioning? Bone Marrow Transplant. 30:2002;797-804.
14. Xia M.Q., et al. Structure of the CAMPATH-1 antigen, a glycosylphosphatidylinositol-anchored glycoprotein which is an exceptionally good target for complement lysis. Biochem. J. 293:1993;633-640.
15. Coiffier B. Monoclonal antibodies combined to chemotherapy for the treatment of patients with lymphoma. Blood Rev. 17:2003;25-31.
16. Press O.W., et al. Immunotherapy of Non-Hodgkin's lymphomas. Hematology (Am. Soc. Hematol. Educ. Program). 1:2001;221-240.
17. Vuist W.M., et al. Lymphoma regression induced by monoclonal anti-idiotypic antibodies correlates with their ability to induce Ig signal transduction and is not prevented by tumour expression of high levels of bcl-2 protein. Blood. 83:1994;899-906.
18. Davis T.A., et al. Anti-idiotype antibodies can induce long-term complete remissions in non-Hodgkin's lymphoma without eradicating the malignant clone. Blood. 92:1998;1184-1190.
19. Glennie M.J., Johnson P.W. Clinical trials of antibody therapy. Immunol. Today. 21:2000;403-410.
20. Stevenson F.K., et al. New strategies for vaccination and imunomodulation in NHL. Ann. Hematol. 80:(Suppl. 3):2001;B132-B134.
21. Agus D.B., et al. Targeting ligand-activated ErbB2 signaling inhibits breast and prostate tumour growth. Cancer Cell. 2:2002;127-137.
22. Leach D.R., et al. Enhancement of antitumour immunity by CTLA-4 blockade. Science. 271:1996;1734-1736.
23. Van Elsas A., et al. Elucidating the autoimmune and antitumour effector mechanisms of a treatment based on cytotoxic T lymphocyte antigen-4 blockade in combination with a B16 melanoma vaccine: comparison of prophylaxis and therapy. J. Exp. Med. 194:2001;481-489.
24. Tutt A.L., et al. T cell immunity to lymphoma following treatment with anti-CD40 monoclonal antibody. J. Immunol. 168:2002;2720-2728.
25. Chen S.H., et al. Rejection of disseminated metastases of colon carcinoma by synergism of IL-12 gene therapy and 4-1BB costimulation. Mol. Ther. 2:2000;39-46.
26. Miller R.E., et al. 4-1BB-specific monoclonal antibody promotes the generation of tumour- specific immune responses by direct activation of CD8 T cells in a CD40- dependent manner. J. Immunol. 169:2002;1792-1800.
27. Tchekmedyian S., et al. MDX-010 (human anti-CTLA4): a phase I clinical trial in malignant melanoma. Am. Soc. Clin. Oncol. Proc. 1:2002;1.
28. Bowne W.B., et al. Coupling and uncoupling of tumour immunity and autoimmunity. J. Exp. Med. 190:1999;1717-1722.
29. Shimizu J., et al. Induction of tumour immunity by removing CD25+CD4+ T cells: a common basis between tumour immunity and autoimmunity. J. Immunol. 163:1999;5211-5218.
30. Carpenter P.A., et al. Non-Fc receptor-binding humanized anti-CD3 antibodies induce apoptosis of activated human T cells. J. Immunol. 165:2000;6205-6213.
31. Presta L.G., et al. Engineering therapeutic antibodies for improved function. Biochem. Soc. Trans. 30:2002;487-490.
32. Milas L., et al. In vivo enhancement of tumour radioresponse by C225 antiepidermal growth factor receptor antibody. Clin. Cancer Res. 6:2000;701-708.
33. Prewett M.C., et al. Enhanced antitumour activity of anti-epidermal growth factor receptor monoclonal antibody IMC-C225 in combination with irinotecan (CPT-11) against human colorectal tumour xenografts. Clin. Cancer Res. 8:2002;994-1003.
34. Harari P.M., Huang S-H. Head and neck cancer as a clinical model for molecular targeting of therapy: combining EGFR blockade with radiation. Int. J. Radiat. Oncol. Biol. Phys. 49:2001;427-433.
35. Bancroft C.C., et al. Effects of pharmacologic antagonists of epidermal growth factor receptor, PI3K and MEK signal kinases on NF-B and AP-1 activation and IL-8 and VEGF expression in human head and neck squamous cell carcinoma lines. Int. J. Cancer. 99:2002;538-548.
36. Vose J.M. Therapeutic uses of MAbs directed against CD20. Cytotherapy. 2:2000;455-461.
37. Vitetta E.S. Immunotoxins and vascular leak syndrome. Cancer J. 6:(Suppl. 3):2000;S218-S224.
38. Dillman R.O. Radiolabeled anti-CD20 monoclonal antibodies for the treatment of B- cell lymphoma. J. Clin. Oncol. 20:2002;3545-3557.
39. Ghetie M.A., et al. Immunotoxins for the treatment of B-cell lymphomas. Mol. Med. 3:1997;420-427.